Coverage Update: Monoclonal Antibody Therapies

As of December 1, 2022, **bebtelovimab is not FDA-approved** and will not be covered by Healthfirst.

Healthfirst will reimburse for bebtelovimab and its administration for dates of service August 15, 2022, through November 30, 2022, under the following HCPCS codes:

- Q0222: Injection, 175mg for the product.

- M0222: Intravenous injection, includes injection and post-administration monitoring.

- M0223: Intravenous injection, includes injection and post-administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency.

Important Reminders

- There is no cost-sharing through the end of the year that the COVID-19 public health emergency ends for monoclonal antibody therapies to treat COVID-19.

- Do not collect copayment, coinsurance, or deductibles for monoclonal antibody therapies to treat COVID-19.

- Providers must **submit paper claims and the invoice** to be reimbursed for commercially purchased bebtelovimab.

Commercially Purchased Bebtelovimab

- Bebtelovimab can be purchased through AmerisourceBergen. Healthfirst will reimburse for purchases made from August 15, 2022, through November 30, 2022.

- Commercially purchased products are identified by Batch # D534422 on the vial.

- As of August 15, 2022, bebtelovimab is no longer allocated by the United States Government. New York State is not purchasing or taking requests for the product.

Additional Resources

FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region

Health Care Provider Fact Sheet

COVID-19 Monoclonal Antibody (mAb) Therapeutics: Information for Providers | Department of Health (ny.gov)

Guidance on How to Request a Supply of COVID-19 Monoclonal Antibody (mAb) and Oral Antiviral Therapeutics

COVID-19 Vaccines and Monoclonal Antibodies | CMS

If you have any questions, please call Provider Services at **1-888-801-1660**, Monday to Friday, 8:30am–5:30pm.